Impact of pneumococcal conjugate vaccines for children in high- and non–high-income countries

References

• Mortality GBD. Causes of Death C: global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2015;385(9963):117–171.
   PubMed Web of Science ®Google Scholar
• Watson DA, Musher DM, Jacobson JW, et al. A brief history of the pneumococcus in biomedical research: a panoply of scientific discovery. Clin Infect Dis. 1993;17(5):913–924.
   PubMed Web of Science ®Google Scholar
• Hennessy TW, Singleton RJ, Bulkow LR, et al. Impact of heptavalent pneumococcal conjugate vaccine on invasive disease, antimicrobial resistance and colonization in Alaska Natives: progress towards elimination of a health disparity. Vaccine. 2005;23(48–49):5464–5473.
   PubMed Web of Science ®Google Scholar
• Segal N, Greenberg D, Dagan R, et al. Disparities in PCV impact between different ethnic populations cohabiting in the same region: A systematic review of the literature. Vaccine. 2016;34(37):4371–4377.
   PubMed Web of Science ®Google Scholar
• Hausdorff WP, Bryant J, Paradiso PR, et al. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis. 2000;30(1):100–121.
   PubMed Web of Science ®Google Scholar
• Hausdorff WP, Siber G, Paradiso PR. Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children. Lancet. 2001;357(9260):950–952.
   PubMed Web of Science ®Google Scholar
• World Bank Country and Lending Groups. https://datahelpdeskworldbankorg/knowledgebase/articles/906519-world-bank-country-and-lending-groups 2017.
   Google Scholar
• O’Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374(9693):893–902.
   PubMed Web of Science ®Google Scholar
• World Health Organisation, Estimated Hib and pneumococcal deaths for children under 5 years of age, 2008 (updated Dec, 2013). http://wwwwhoint/immunization/monitoring_surveillance/burden/estimates/Pneumo_hib/en/2013.
   Google Scholar
• Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J. 2000;19(3):187–195.
   PubMed Web of Science ®Google Scholar
• Black SB, Shinefield HR, Ling S, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J. 2002;21(9):810–815.
   PubMed Web of Science ®Google Scholar
• Feikin DR, Kagucia EW, Loo JD, et al. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. Plos Med. 2013;10(9):e1001517.
   PubMed Web of Science ®Google Scholar
• Lepoutre A, Varon E, Georges S, et al. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012. Vaccine. 2015;33(2):359–366.
   PubMed Web of Science ®Google Scholar
• Miller E, Andrews NJ, Waight PA, et al. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis. 2011;11(10):760–768.
   PubMed Web of Science ®Google Scholar
• Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201(1):32–41.
   PubMed Web of Science ®Google Scholar
• Pneumococcal conjugate vaccine for childhood immunization–WHO position paper. Wkly Epidemiol Rec. 2007;82(12):93–104.
   PubMedGoogle Scholar
• Hausdorff WP. The roles of pneumococcal serotypes 1 and 5 in paediatric invasive disease. Vaccine. 2007;25(13):2406–2412.
   PubMed Web of Science ®Google Scholar
• Hausdorff WP, Dagan R, Beckers F, et al. Estimating the direct impact of new conjugate vaccines against invasive pneumococcal disease. Vaccine. 2009;27(52):7257–7269.
   PubMed Web of Science ®Google Scholar
• Andrade AL, Minamisava R, Policena G, et al. Evaluating the impact of PCV-10 on invasive pneumococcal disease in Brazil: A time-series analysis. Hum Vaccin Immunother. 2016;12(2):285–292.
   PubMed Web of Science ®Google Scholar
• Baldovin T, Lazzari R, Russo F, et al. A surveillance system of Invasive Pneumococcal Disease in North-Eastern Italy. Ann Ig. 2016;28(1):15–24.
   PubMedGoogle Scholar
• Ben-Shimol S, Greenberg D, Givon-Lavi N, et al. Impact of PCV7/PCV13 introduction on invasive pneumococcal disease (IPD) in young children: comparison between meningitis and non-meningitis IPD. Vaccine. 2016;34(38):4543–4550.
   PubMed Web of Science ®Google Scholar
• Chacon-Cruz E, Rivas-Landeros RM, Volker-Soberanes ML. Early trends in invasive pneumococcal disease in children following the introduction of 13-valent pneumococcal conjugate vaccine: results from eight years of active surveillance in a Mexican hospital. Ther Adv Vaccines. 2014;2(6):155–158.
   PubMedGoogle Scholar
• Deceuninck G, De Serres G, Boulianne N, et al. Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada. Vaccine. 2015;33(23):2684–2689.
   PubMed Web of Science ®Google Scholar
• Farnham AC, Zimmerman CM, Papadouka V, et al. Invasive pneumococcal disease following the introduction of 13-valent conjugate vaccine in children in New York city from 2007 to 2012. JAMA Pediatr. 2015;169(7):646–652.
   PubMed Web of Science ®Google Scholar
• Harboe ZB, Dalby T, Weinberger DM, et al. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis. 2014;59(8):1066–1073.
   PubMed Web of Science ®Google Scholar
• Jokinen J, Rinta-Kokko H, Siira L, et al. Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children–a population-based study. Plos One. 2015;10(3):e0120290.
   PubMed Web of Science ®Google Scholar
• Waight PA, Andrews NJ, Ladhani NJ, et al. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis. 2015;15(6):629.
   PubMed Web of Science ®Google Scholar
• Palmu AA, Jokinen J, Nieminen H, et al. Vaccine effectiveness of the pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against clinically suspected invasive pneumococcal disease: a cluster-randomised trial. Lancet Respir Med. 2014;2(9):717–727.
   PubMed Web of Science ®Google Scholar
• Rodgers GL. Klugman KP: surveillance of the impact of pneumococcal conjugate vaccines in developing countries. Hum Vaccin Immunother. 2016;12(2):417–420.
   PubMed Web of Science ®Google Scholar
• Gavi, The Vaccine Alliance, 2015 Pneumococcal AMC. Annual Report. wwwgaviorg/funding/2015.
   Google Scholar
• Cohen R, Varon E, Doit C, et al. A 13-year survey of pneumococcal nasopharyngeal carriage in children with acute otitis media following PCV7 and PCV13 implementation. Vaccine. 2015;33(39):5118–5126.
   PubMed Web of Science ®Google Scholar
• Cohen C, Von Mollendorf C, De Gouveia L, et al. Effectiveness of 7-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in HIV-infected and -uninfected children in south africa: a matched case-control study. Clin Infect Dis. 2014;59(6):808–818.
   PubMed Web of Science ®Google Scholar
• Cohen C, Von Mollendorf C, De Gouveia L, et al. Effectiveness of the 13-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in south african children: a case-control study. Lancet Global Health. 2017;5(3):359–369.
   Web of Science ®Google Scholar
• Ben-Shimol S, Givon-Lavi N, Leibovitz E, et al. Near-elimination of otitis media caused by 13-valent pneumococcal conjugate vaccine (PCV) serotypes in southern Israel shortly after sequential introduction of 7-valent/13-valent PCV. Clin Infect Dis. 2014;59(12):1724–1732.
   PubMed Web of Science ®Google Scholar
• Zhou F, Shefer A, Kong Y, et al. Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997-2004. Pediatrics. 2008;121(2):253–260.
   PubMed Web of Science ®Google Scholar
• Palmu AA, Verho J, Jokinen J, et al. The seven-valent pneumococcal conjugate vaccine reduces tympanostomy tube placement in children. Pediatr Infect Dis J. 2004;23(8):732–738.
   PubMed Web of Science ®Google Scholar
• Lau WC, Murray M, El-Turki A, et al. Impact of pneumococcal conjugate vaccines on childhood otitis media in the United Kingdom. Vaccine. 2015;33(39):5072–5079.
   PubMed Web of Science ®Google Scholar
• Suarez V, Michel F, Toscano CM, et al. Impact of pneumococcal conjugate vaccine in children morbidity and mortality in Peru: time series analyses. Vaccine. 2016;34(39):4738–4743.
   PubMed Web of Science ®Google Scholar
• Black S, Shinefield H, Baxter R, et al. Impact of the use of heptavalent pneumococcal conjugate vaccine on disease epidemiology in children and adults. Vaccine. 2006;24(Suppl 2):S2-79-80.
   Google Scholar
• Regev-Yochay G, Paran Y, Bishara J, et al. Early impact of PCV7/PCV13 sequential introduction to the national pediatric immunization plan, on adult invasive pneumococcal disease: A nationwide surveillance study. Vaccine. 2015;33(9):1135–1142.
   PubMed Web of Science ®Google Scholar
• Von Gottberg A, de Gouveia L, Tempia S, et al. Effects of vaccination on invasive pneumococcal disease in South Africa. N Engl J Med. 2014;371(20):1889–1899.
   PubMed Web of Science ®Google Scholar
• Hanquet G, Perrocheau A, Kissling E, et al. Surveillance of invasive pneumococcal disease in 30 EU countries: towards a European system? Vaccine. 2010;28(23):3920–3928.
   PubMed Web of Science ®Google Scholar
• Stock NK, Maly M, Sebestova H, et al. The czech surveillance system for invasive pneumococcal disease, 2008-2013: a follow-up assessment and sensitivity estimation. Plos One. 2015;10(6):e0131117.
   PubMed Web of Science ®Google Scholar
• Madhi SA, Nunes MC. The potential impact of pneumococcal conjugate vaccine in Africa: considerations and early lessons learned from the South African experience. Hum Vaccin Immunother. 2016;12(2):314–325.
   PubMed Web of Science ®Google Scholar
• Mackenzie GA, Hill PC, Jeffries DJ, et al. Effect of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease in The Gambia: a population-based surveillance study. Lancet Infect Dis. 2016;16(6):703–711.
   PubMed Web of Science ®Google Scholar
• Weil-Olivier C, van der Linden M, De Schutter I, et al. Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective. BMC Infect Dis. 2012;12:207.
   PubMed Web of Science ®Google Scholar
• Madhi SA, Groome MJ, Zar HJ, et al. Effectiveness of pneumococcal conjugate vaccine against presumed bacterial pneumonia hospitalisation in HIV-uninfected South African children: a case-control study. Thorax. 2015;70(12):1149–1155.
   PubMed Web of Science ®Google Scholar
• Scotta MC, Veras TN, Klein PC, et al. Impact of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) on childhood pneumonia hospitalizations in Brazil two years after introduction. Vaccine. 2014;32(35):4495–4499.
   PubMed Web of Science ®Google Scholar
• Hortal M, Estevan M, Meny M, et al. Impact of pneumococcal conjugate vaccines on the incidence of pneumonia in hospitalized children after five years of its introduction in Uruguay. Plos One. 2014;9(6):e98567.
   PubMed Web of Science ®Google Scholar
• Gatera M, Uwimana J, Manzi E, et al. Use of administrative records to assess pneumococcal conjugate vaccine impact on pediatric meningitis and pneumonia hospitalizations in Rwanda. Vaccine. 2016;34(44):5321–5328.
   PubMed Web of Science ®Google Scholar
• Diaz J, Terrazas S, Bierrenbach AL, et al. Effectiveness of the 10-Valent Pneumococcal Conjugate Vaccine (PCV-10) in children in chile: a nested case-control study using nationwide pneumonia morbidity and mortality surveillance data. Plos One. 2016;11(4):e0153141.
   PubMed Web of Science ®Google Scholar
• Becker-Dreps S, Amaya E, Liu L, et al. Changes in childhood pneumonia and infant mortality rates following introduction of the 13-valent pneumococcal conjugate vaccine in Nicaragua. Pediatr Infect Dis J. 2014;33(6):637–642.
   PubMed Web of Science ®Google Scholar
• Angoulvant F, Levy C, Grimprel E, et al. Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children. Clin Infect Dis. 2014;58(7):918–924.
   PubMed Web of Science ®Google Scholar
• Noel G, Viudes G, Laporte R, et al. Evaluation of the impact of pneumococcal conjugate vaccine on pediatric community-acquired pneumonia using an emergency database system. J Pediatric Infect Dis Soc. 2016.
   PubMed Web of Science ®Google Scholar
• Nair H, Watts AT, Williams LJ, et al. Pneumonia hospitalisations in Scotland following the introduction of pneumococcal conjugate vaccination in young children. BMC Infect Dis. 2016;16:390.
   PubMed Web of Science ®Google Scholar
• Kaplan SL, Barson WJ, Lin PL, et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2013;32(3):203–207.
   PubMed Web of Science ®Google Scholar
• Palmu AA, Kilpi TM, Rinta-Kokko H, et al. Pneumococcal conjugate vaccine and clinically suspected invasive pneumococcal disease. Pediatrics. 2015;136(1):e22–27.
   PubMed Web of Science ®Google Scholar
• Simonsen L, Taylor RJ, Schuck-Paim C, et al. Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis. Lancet Respir Med. 2014;2(5):387–394.
   PubMed Web of Science ®Google Scholar
• Iroh Tam PY, Madoff LC, Coombes B, et al. Invasive pneumococcal disease after implementation of 13-valent conjugate vaccine. Pediatrics. 2014;134(2):210–217.
   PubMed Web of Science ®Google Scholar
• Moore MR, Link-Gelles R, Schaffner W, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015;15(3):301–309.
   PubMed Web of Science ®Google Scholar
• Olarte L, Barson WJ, Barson RM, et al. Impact of the 13-valent pneumococcal conjugate vaccine on pneumococcal meningitis in US children. Clin Infect Dis. 2015;61(5):767–775.
   PubMed Web of Science ®Google Scholar
• Ben-Shimol S, Greenberg D, Givon-Lavi N, et al. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance. Vaccine. 2014;32(27):3452–3459.
   PubMed Web of Science ®Google Scholar
• Levy C, Varon E, Picard C, et al. Trends of pneumococcal meningitis in children after introduction of the 13-valent pneumococcal conjugate vaccine in France. Pediatr Infect Dis J. 2014;33(12):1216–1221.
   PubMed Web of Science ®Google Scholar
• Levy C, Varon E, Bechet S, et al. Effect of the 13-valent pneumococcal conjugate vaccine on pneumococcal meningitis in children. Clin Infect Dis. 2016;62(1):131–132.
   PubMed Web of Science ®Google Scholar
• Varon E, Cohen R, Bechet S, et al. Invasive disease potential of pneumococci before and after the 13-valent pneumococcal conjugate vaccine implementation in children. Vaccine. 2015;33(46):6178–6185.
   PubMed Web of Science ®Google Scholar
• Cohen R, Varon E, Bechet S, et al. Comparative impact of pneumococcal conjugate vaccines on pneumococcal meningitis according to underlying conditions. Vaccine. 2016;34(41):4850–4856.
   PubMed Web of Science ®Google Scholar
• Wei SH, Chiang CS, Chiu CH, et al. Pediatric invasive pneumococcal disease in Taiwan following a national catch-up program with the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2015;34(3):e71–77.
   PubMed Web of Science ®Google Scholar
• Wei SH, Chiang CS, Chen CL, et al. Pneumococcal disease and use of pneumococcal vaccines in Taiwan. Clin Exp Vaccine Res. 2015;4(2):121–129.
   PubMed Web of Science ®Google Scholar
• Su WJ, Lo HY, Chang CH, et al. Effectiveness of pneumococcal conjugate vaccines of different valences against invasive pneumococcal disease among children in taiwan: a nationwide study. Pediatr Infect Dis J. 2016;35(4):e124–133.
   PubMed Web of Science ®Google Scholar
• van der Linden M, Falkenhorst G, Perniciaro S, et al. Effects of infant pneumococcal conjugate vaccination on serotype distribution in invasive pneumococcal disease among children and adults in Germany. Plos One. 2015;10(7):e0131494.
   PubMed Web of Science ®Google Scholar
• Imohl M, Moller J, Reinert RR, et al. Pneumococcal meningitis and vaccine effects in the era of conjugate vaccination: results of 20 years of nationwide surveillance in Germany. BMC Infect Dis. 2015;15:61.
   PubMed Web of Science ®Google Scholar
• van der Linden M, Falkenhorst G, Perniciaro S, et al. Effectiveness of Pneumococcal Conjugate Vaccines (PCV7 and PCV13) against invasive pneumococcal disease among children under two years of age in Germany. Plos One. 2016;11(8):e0161257.
   PubMed Web of Science ®Google Scholar
• Guevara M, Barricarte A, Torroba L, et al. Direct, indirect and total effects of 13-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in children in Navarra, Spain, 2001 to 2014: cohort and case-control study. Euro Surveill. 2016;21(14).
   PubMedGoogle Scholar
• Jayasinghe S, Menzies R, Chiu C, et al. Long-term Impact of a “3 + 0” Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, R2002-2014. Clin Infect Dis. 2017;64(2):175–183.
   PubMed Web of Science ®Google Scholar
• Browall S, Backhaus E, Naucler P, et al. Clinical manifestations of invasive pneumococcal disease by vaccine and non-vaccine types. Eur Respir J. 2014;44(6):1646–1657.
   PubMed Web of Science ®Google Scholar
• Ladhani SN, Andrews NJ, Waight P, et al. Invasive pneumococcal disease, comorbidities, and polysaccharide vaccine use in children aged 5-15 years in England and Wales. Clin Infect Dis. 2014;58(4):517–525.
   PubMed Web of Science ®Google Scholar
• Pelton SI. The challenge of preventing invasive pneumococcal disease in children with comorbid illnesses. Clin Infect Dis. 2014;58(4):526–527.
   PubMed Web of Science ®Google Scholar
• Ceyhan M, Ozsurekci Y, Gurler N, et al. Serotype distribution of Streptococcus pneumoniae in children with invasive diseases in Turkey: 2008-2014. Hum Vaccin Immunother. 2016;12(2):308–313.
   PubMed Web of Science ®Google Scholar
• Garcia Gabarrot G, Lopez Vega M, Perez Giffoni G, et al. Effect of pneumococcal conjugate vaccination in Uruguay, a middle-income country. Plos One. 2014;9(11):e112337.
   PubMed Web of Science ®Google Scholar
• Diawara I, Zerouali K, Katfy K, et al. Invasive pneumococcal disease among children younger than 5 years of age before and after introduction of pneumococcal conjugate vaccine in Casablanca, Morocco. Int J Infect Dis. 2015;40:95–101.
   PubMed Web of Science ®Google Scholar
• Verani JR, Domingues CM, De Moraes JC, et al. Indirect cohort analysis of 10-valent pneumococcal conjugate vaccine effectiveness against vaccine-type and vaccine-related invasive pneumococcal disease. Vaccine. 2015;33(46):6145–6148.
   PubMed Web of Science ®Google Scholar
• Hirose TE, Maluf EM. Rodrigues CO: pneumococcal meningitis: epidemiological profile pre- and post-introduction of the pneumococcal 10-valent conjugate vaccine. J Pediatr (Rio J). 2015;91(2):130–135.
   PubMed Web of Science ®Google Scholar
• Grando IM, Moraes C, Flannery B, et al. Impact of 10-valent pneumococcal conjugate vaccine on pneumococcal meningitis in children up to two years of age in Brazil. Cad Saude Publica. 2015;31(2):276–284.
   PubMed Web of Science ®Google Scholar
• de Oliveira LH, Camacho LA, Coutinho ES, et al. Impact and effectiveness of 10 and 13-valent pneumococcal conjugate vaccines on hospitalization and mortality in children aged less than 5 years in Latin American countries: a systematic review. Plos One. 2016;11(12):e0166736.
   PubMed Web of Science ®Google Scholar
• Berglund A, Ekelund M, Fletcher MA, et al. All-cause pneumonia hospitalizations in children <2 years old in sweden, 1998 to 2012: impact of pneumococcal conjugate vaccine introduction. Plos One. 2014;9(11):e112211.
   PubMed Web of Science ®Google Scholar
• Griffin MR, Mitchel E, Moore MR, et al. Declines in pneumonia hospitalizations of children aged <2 years associated with the use of pneumococcal conjugate vaccines - Tennessee, 1998-2012. MMWR Morb Mortal Wkly Rep. 2014;63(44):995–998.
   PubMed Web of Science ®Google Scholar
• Lindstrand A, Bennet R, Galanis I, et al. Sinusitis and pneumonia hospitalization after introduction of pneumococcal conjugate vaccine. Pediatrics. 2014;134(6):e1528–1536.
   PubMed Web of Science ®Google Scholar
• Greenberg D, Givon-Lavi N, Ben-Shimol S, et al. Impact of PCV7/PCV13 introduction on community-acquired alveolar pneumonia in children <5 years. Vaccine. 2015;33(36):4623–4629.
   PubMed Web of Science ®Google Scholar
• Baldo V, Cocchio S, Gallo T, et al. Impact of pneumococcal conjugate vaccination: a retrospective study of hospitalization for pneumonia in North-East Italy. J Prev Med Hyg. 2016;57(2):E61–68.
   PubMedGoogle Scholar
• Georgalis L, Mozalevskis A, Martinez De Aragon MV, et al. Changes in the pneumococcal disease-related hospitalisations in Spain after the replacement of 7-valent by 13-valent conjugate vaccine. Eur J Clin Microbiol Infect Dis. 2017;36(3):575–583.
   PubMed Web of Science ®Google Scholar
• Pirez MC, Algorta G, Chamorro F, et al. Changes in hospitalizations for pneumonia after universal vaccination with pneumococcal conjugate vaccines 7/13 valent and haemophilus influenzae type b conjugate vaccine in a pediatric referral hospital in Uruguay. Pediatr Infect Dis J. 2014;33(7):753–759.
   PubMed Web of Science ®Google Scholar
• Afonso ET, Minamisava R, Bierrenbach AL, et al. Effect of 10-valent pneumococcal vaccine on pneumonia among children, Brazil. Emerg Infect Dis. 2013;19(4):589–597.
   PubMed Web of Science ®Google Scholar
• Sgambatti S, Minamisava R, Bierrenbach AL, et al. Early impact of 10-valent pneumococcal conjugate vaccine in childhood pneumonia hospitalizations using primary data from an active population-based surveillance. Vaccine. 2016;34(5):663–670.
   PubMed Web of Science ®Google Scholar
• McCollum ED, Nambiar B, Deula R, et al. Impact of the 13-valent pneumococcal conjugate vaccine on clinical and hypoxemic childhood pneumonia over three years in central malawi: an observational study. Plos One. 2017;12(1):e0168209.
   PubMed Web of Science ®Google Scholar
• Bogaert D, Keijser B, Huse S, et al. Variability and diversity of nasopharyngeal microbiota in children: a metagenomic analysis. Plos One. 2011;6(2):e17035.
   PubMed Web of Science ®Google Scholar
• Simell B, Auranen K, Kayhty H, et al. The fundamental link between pneumococcal carriage and disease. Expert Rev Vaccines. 2012;11(7):841–855.
   PubMed Web of Science ®Google Scholar
• Flasche S, Givon-Lavi N, Dagan R. Using pneumococcal carriage data to monitor postvaccination changes in the incidence of pneumococcal otitis media. Am J Epidemiol. 2016;184(9):652–659.
   PubMed Web of Science ®Google Scholar
• Flasche S, Van Hoek AJ, Sheasby E, et al. Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study. Plos Med. 2011;8(4):e1001017.
   PubMed Web of Science ®Google Scholar
• Ginsburg AS, Nahm MH, Khambaty FM, et al. Issues and challenges in the development of pneumococcal protein vaccines. Expert Rev Vaccines. 2012;11(3):279–285.
   PubMed Web of Science ®Google Scholar
• Khan MN. Pichichero ME: the host immune dynamics of pneumococcal colonization: implications for novel vaccine development. Hum Vaccin Immunother. 2014;10(12):3688–3699.
   PubMed Web of Science ®Google Scholar
• Li Y, Weinberger DM, Thompson CM, et al. Surface charge of Streptococcus pneumoniae predicts serotype distribution. Infect Immun. 2013;81(12):4519–4524.
   PubMed Web of Science ®Google Scholar
• Weinberger DM, Trzcinski K, Lu YJ, et al. Pneumococcal capsular polysaccharide structure predicts serotype prevalence. Plos Pathog. 2009;5(6):e1000476.
   PubMed Web of Science ®Google Scholar
• Hedlund J, Sorberg M, Henriques Normark B, et al. Capsular types and antibiotic susceptibility of invasive Streptococcus pneumoniae among children in Sweden. Scand J Infect Dis. 2003;35(8):452–458.
   PubMed Web of Science ®Google Scholar
• Normark BH, Ortqvist A, Kalin M, et al. Changes in serotype distribution may hamper efficacy of pneumococcal conjugate vaccines in children. Scand J Infect Dis. 2001;33(11):848–850.
   PubMedGoogle Scholar
• Dagan R, Leibovitz E, Greenberg D, et al. Mixed pneumococcal-nontypeable Haemophilus influenzae otitis media is a distinct clinical entity with unique epidemiologic characteristics and pneumococcal serotype distribution. J Infect Dis. 2013;208(7):1152–1160.
   PubMed Web of Science ®Google Scholar
• Greenberg D, Givon-Lavi N, Newman N, et al. Nasopharyngeal carriage of individual Streptococcus pneumoniae serotypes during pediatric pneumonia as a means to estimate serotype disease potential. Pediatr Infect Dis J. 2011;30(3):227–233.
   PubMed Web of Science ®Google Scholar
• Yildirim I, Hanage WP, Lipsitch M, et al. Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease. Vaccine. 2010;29(2):283–288.
   PubMed Web of Science ®Google Scholar
• Chang Q, Stevenson AE, Croucher NJ, et al. Stability of the pneumococcal population structure in Massachusetts as PCV13 was introduced. BMC Infect Dis. 2015;15:68.
   PubMed Web of Science ®Google Scholar
• Lindstrand A, Galanis I, Darenberg J, et al. Unaltered pneumococcal carriage prevalence due to expansion of non-vaccine types of low invasive potential 8years after vaccine introduction in Stockholm, Sweden. Vaccine. 2016;34(38):4565–4571.
   PubMed Web of Science ®Google Scholar
• Mehtala J, Antonio M, Kaltoft MS, et al. Competition between Streptococcus pneumoniae strains: implications for vaccine-induced replacement in colonization and disease. Epidemiology. 2013;24(4):522–529.
   PubMed Web of Science ®Google Scholar
• Hausdorff WP. Hanage WP: interim results of an ecological experiment - Conjugate vaccination against the pneumococcus and serotype replacement. Hum Vaccin Immunother. 2016;12(2):358–374.
   PubMed Web of Science ®Google Scholar
• Cohen R, Levy C, de La Rocque F, et al. Impact of pneumococcal conjugate vaccine and of reduction of antibiotic use on nasopharyngeal carriage of nonsusceptible pneumococci in children with acute otitis media. Pediatr Infect Dis J. 2006;25(11):1001–1007.
   PubMed Web of Science ®Google Scholar
• Mitchell PK, Lipsitch M. Hanage WP: carriage burden, multiple colonization and antibiotic pressure promote emergence of resistant vaccine escape pneumococci. Philos Trans R Soc Lond B Biol Sci. 2015;370(1670):20140342.
   PubMed Web of Science ®Google Scholar
• Choe YJ, Lee HJ, Lee H, et al. Emergence of antibiotic-resistant non-vaccine serotype pneumococci in nasopharyngeal carriage in children after the use of extended-valency pneumococcal conjugate vaccines in Korea. Vaccine. 2016;34(40):4771–4776.
   PubMed Web of Science ®Google Scholar
• Loo JD, Conklin L, Fleming-Dutra KE, et al. Systematic review of the indirect effect of pneumococcal conjugate vaccine dosing schedules on pneumococcal disease and colonization. Pediatr Infect Dis J. 2014;33(Suppl 2):S161–171.
   PubMed Web of Science ®Google Scholar
• Cohen R, Bingen E, Levy C, et al. Nasopharyngeal flora in children with acute otitis media before and after implementation of 7 valent pneumococcal conjugate vaccine in France. BMC Infect Dis. 2012;12:52.
   PubMed Web of Science ®Google Scholar
• Roca A, Dione MM, Bojang A, et al. Nasopharyngeal carriage of pneumococci four years after community-wide vaccination with PCV-7 in The Gambia: long-term evaluation of a cluster randomized trial. Plos One. 2013;8(9):e72198.
   PubMed Web of Science ®Google Scholar
• Donkor ES, Bishop CJ, Gould K, et al. High levels of recombination among Streptococcus pneumoniae isolates from the Gambia. MBio. 2011;2(3):e00040–00011.
   PubMed Web of Science ®Google Scholar
• Brueggemann AB, Peto TE, Crook DW, et al. Temporal and geographic stability of the serogroup-specific invasive disease potential of Streptococcus pneumoniae in children. J Infect Dis. 2004;190(7):1203–1211.
   PubMed Web of Science ®Google Scholar
• Hanage WP, Kaijalainen TH, Syrjanen RK, et al. Invasiveness of serotypes and clones of Streptococcus pneumoniae among children in Finland. Infect Immun. 2005;73(1):431–435.
   PubMed Web of Science ®Google Scholar
• Shouval DS, Greenberg D, Givon-Lavi N, et al. Site-specific disease potential of individual Streptococcus pneumoniae serotypes in pediatric invasive disease, acute otitis media and acute conjunctivitis. Pediatr Infect Dis J. 2006;25(7):602–607.
   PubMed Web of Science ®Google Scholar
• Hausdorff WP, Bryant J, Kloek C, et al. The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. Clin Infect Dis. 2000;30(1):122–140.
   PubMed Web of Science ®Google Scholar
• Sobanjo-Ter Meulen A, Vesikari T, Malacaman EA, et al. Safety, tolerability and immunogenicity of 15-valent pneumococcal conjugate vaccine in toddlers previously vaccinated with 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2015;34(2):186–194.
   PubMed Web of Science ®Google Scholar
• Moffitt K, Malley R. Rationale and prospects for novel pneumococcal vaccines. Hum Vaccin Immunother. 2016;12(2):383–392.
   PubMed Web of Science ®Google Scholar
• Daniels CC, Rogers PD, Shelton CM. A review of pneumococcal vaccines: current polysaccharide vaccine recommendations and future protein antigens. J Pediatr Pharmacol Ther. 2016;21(1):27–35.
   PubMedGoogle Scholar